Introduction
============

The anaphase-promoting complex/cyclosome (APC/C)[\*](#fn1){ref-type="fn"} is a conserved multi-component ubiquitin ligase, which controls the proteolysis of several key cell cycle proteins ([@bib14]; [@bib17]; [@bib41]; [@bib42]; for reviews see [@bib26]; [@bib47]). In budding yeast, these include at least four of the six yeast B-type cyclins (Clb1p--Clb3p and Clb5p) ([@bib14]; [@bib13]; [@bib32]), Dbf4, a regulator of DNA replication ([@bib6]; [@bib23]; [@bib10]), the anaphase inhibitor Pds1p ([@bib7]), the polo-like kinase Cdc5p ([@bib5]), the APC/C regulator Cdc20p ([@bib29]; [@bib36]), the checkpoint kinase Hsl ([@bib4]), and the spindle midzone protein Ase1p ([@bib16]). The tryptophan aspartic acid repeat proteins Cdc20p and Cdh1p/Hct1p are substoichiometric APC/C components that are proposed to be substrate-specific APC/C activators ([@bib32]; [@bib44]). Based on its association with either of these two activators, the APC/C is thought to have two functionally distinct forms: APC^Cdc20^ and APC^Cdh1^ ([@bib25]).

To coordinate a normal cell cycle, these two APC/C activities must be linked either directly or indirectly to cyclin-dependent kinase (CDK) activity. For APC^Cdh1^, the linkage is thought to take place primarily through CDK phosphorylation of Cdh1p. In yeast, Cdh1p levels are constant throughout the cell cycle, but its binding to APC/C is blocked by CDK phosphorylation ([@bib48]; [@bib15]). At the end of mitosis, APC^Cdh1^ is activated because Cdh1p is dephosphorylated and binds APC/C. Both the drop in mitotic kinase activity and the activation of the phosphatase Cdc14p contribute to Cdh1p dephosphorylation during mitotic exit ([@bib45]; [@bib38]). Eventually, APC^Cdh1^ is inactivated in the next cell cycle by rising CDK activity. However, the precise timing of APC^Cdh1^ inactivation and the CDK isoforms involved have not been determined clearly. The experimental evidence to date supports the view that G1 CDKs alone inactivate what is now known to be APC^Cdh1^ ([@bib3]). Additionally, the possibility that S phase cyclins could have a role in APC^Cdh1^ inactivation has been raised because failure to degrade an S phase cyclin by the end of mitosis can block APC^Cdh1^ function and mitotic exit ([@bib37]; [@bib47]).

During G1, APC^Cdh1^ activity is required to prevent expression of proteins that may interfere with bud emergence, lead to premature DNA replication, or disturb spindle assembly ([@bib3]; [@bib13]; [@bib16]). Before the onset of the ensuing mitosis, APC^Cdh1^ must be turned off in order to allow its mitotic substrates to accumulate. Several lines of evidence linked G1 CDK activity (Cln1p-Cln3p bound to Cdk1p) to the inactivation of APC^Cdh1^. First, in *cdc4*-arrested cells, which block in late G1 with high levels of G1 CDK activity, ectopically expressed M phase B-type cyclin Clb2p was stable, and its stability required the expression of G1 cyclins ([@bib3]; [@bib1]). Second, the accumulation of a constitutively expressed Clb2p correlated with the rise in G1 cyclin expression that occurs in G1 ([@bib3]). Finally, Cdh1p was heavily phosphorylated and presumed to be inactive in late G1-arrested cells ([@bib48]). Together, these experiments suggested that G1 CDK phosphorylation of Cdh1p was the mechanism for inactivating APC^Cdh1^. However, these experiments were potentially complicated by the fact that Clb2p is not only an APC/C substrate but also an APC/C regulator whose expression might influence its own stability ([@bib1]).

Unexpectedly, we found that another APC^Cdh1^ substrate, the microtubule-binding protein Ase1p, was rapidly degraded in late G1 (*cdc4* block). Further, Ase1p degradation at this arrest point had the hallmarks of APC^Cdh1^-dependent proteolysis: it required both the Ase1p destruction box and Cdh1p. A minimal Ase1p sequence for APC^Cdh1^-mediated degradation was defined whose constitutive expression did not affect cell cycle progression. Using this degradation signal to monitor APC^Cdh1^ activity in vivo, we found that APC^Cdh1^ is inactivated during S phase and that the S phase cyclin Clb5p was required for the normal timing of APC^Cdh1^ inactivation. Further, we show that the degradation of Cdc20p in late G1 is also APC^Cdh1^ dependent and that premature expression of Cdc20p delays the progression through S phase. These findings suggest that both G1 and S phase cyclins are required to shut off APC^Cdh1^ and that APC^Cdh1^ activity in G1 plays an important role in ensuring the proper timing of Cdc20p expression.

Results
=======

In budding yeast, genetic and biochemical analyses have defined several molecular events necessary for transit through G1 and into S phase. CDK activity is low in early G1 but rises in late G1 when G1 cyclins are expressed. The rise in G1 CDK activity induces apical bud growth and initiates a cascade of events that leads to the phosphorylation and subsequent degradation of the B-type cyclin/CDK inhibitor Sic1p. Sic1p degradation permits the activation of S phase CDKs (Cdk1p bound to Clb5p and Clb6p, two of the six B-type cyclins in yeast) and therefore the initiation of S phase (for review see [@bib20]).

To determine if Ase1p destruction was inactivated by G1 CDK activity, the half-life of Ase1p was determined in a *cdc4* mutant, which arrests before S phase with high G1 CDK activity and high levels of Sic1p. We found that Ase1p is rapidly degraded at the *cdc4* block with similar kinetics to that observed previously in α-factor--arrested cells ([Fig. 1](#fig1){ref-type="fig"} A; [@bib16]). The 5--10 min half-life of Ase1p at the *cdc4* arrest point contrasts sharply with the \>60 min half-life of Ase1p observed in cycling or nocodazole-arrested cells ([@bib16]; data not shown). Ase1p is also rapidly degraded in a *skp1-11* strain, which also arrests in late G1 (data not shown). This also contrasts with the degradation of the APC^Cdh1^ substrate Clb2p, which is stable at the *cdc4* block ([@bib3]; [@bib1]; unpublished data; see [Fig. 4](#fig4){ref-type="fig"} B, glu). Like Ase1p degradation in α-factor--arrested cells, Ase1p degradation at the *cdc4* block required Cdh1p and the destruction box (db), a cis-acting sequence for APC/C-mediated degradation ([Fig. 1, A and B](#fig1){ref-type="fig"}). Therefore, Ase1p is rapidly degraded by APC^Cdh1^ in the presence of high levels of G1 CDK activity.

![**APC^Cdh1^ is active in late G1.** (A) *cdc4* strains containing *GAL1,10*::*ASE1* or *GAL1,10::ASE1-DB* ([@bib16]) were arrested in yeast extract and peptone (YEP) raffinose at 36°C. Expression from the *GAL1,10* promoter was induced for 60 min, and the half-life of Ase1p or Ase1p-db was determined. G1 arrest was confirmed by FACS^®^. (B) The half-life of Ase1p was determined in arrested *cdc4 cdh1*Δ*clb6*Δ and *cdc4 CDH1 clb6*Δ strains as above. The *clb6*Δ mutation was introduced into these strains to promote efficient arrest. *cdc4 cdh1*Δ double mutants arrest poorly in late G1, probably because of persistent low levels of B-type cyclins from the previous mitosis (unpublished data). (C) *cdc4* strains containing an epitope-tagged APC/C subunit (Cdc16p-myc6), or the untagged control, and HA-tagged Cdh1p (HA3-Cdh1p) were arrested at 36°C, and APC/C was immunoprecipitated using a monoclonal antibody directed against the myc epitope. Extracts and immunoprecipitates were probed with 12CA5 to detect HA3-Cdh1p.](0102007f1){#fig1}

![**Overexpression of Sic1p increases Clb2p turnover at the *cdc4* block.** (A) Overexpression of Sic1 blocks Clb2p accumulation at the *cdc4* block. A *cdc4* strain expressing Clb2p-HA3 from the methionine-repressible *MET25* ([@bib22]) promoter and Sic1p-HA from the *GAL1,10* promoter ([@bib43]) were arrested with α-factor and released at the nonpermissive temperature to arrest at the *cdc4* block. After release, the culture was split, and Sic1p-HA expression was induced by the addition of galactose (gal) in one culture and repressed in the other with glucose (glu). The two cultures were kept at 36°C, until the cells were arrested with elongated buds and G1 DNA content. The levels of Clb2p-HA3 and Sic1p-HA were determined by Western blotting, and *CLB2* mRNA levels were determined by Northern blotting. The *MET25* promoter expresses at low levels even under the repressing conditions of this experiment (medium containing methionine). (B) Sic1p overexpression restores Clb2p degradation in *cdc4*-arrested cells. The strain used in A was treated as above, and the half-life of Clb2p-HA3 was determined after expression was shut off by the addition of methionine and cycloheximide.](0102007f4){#fig4}

The rapid degradation of Ase1p in *cdc4*-arrested cells prompted us to determine if Cdh1p could bind APC/C in *cdc4*-arrested cells. Unphosphorylated Cdh1p binds to APC/C strongly, whereas CDK-phosphorylated Cdh1p does not ([@bib48]; [@bib15]). Cdh1p was found previously to be heavily phosphorylated in cells arrested in late G1 ([@bib48]). We also found that Cdh1p appears to be phosphorylated in *cdc4*-arrested cells, although judging from its mobility it appears to be less phosphorylated than in nocodazole-arrested cells ([Fig. 1](#fig1){ref-type="fig"} C, input). Consistent with the apparent activity of APC^Cdh1^ at the *cdc4* block, Cdh1p was coimmunoprecipitated with APC/C in *cdc4*-arrested cells. The coimmunoprecipitation experiments suggest that the amount of APC^Cdh1^ diminishes in a graded manner during G1: high levels of Cdh1p coimmunoprecipitate with Cdc16p in α-factor--arrested cells, low levels of Cdh1p coimmunoprecipitate in *cdc4*-arrested cells, and coimmunoprecipitation is undetectable in nocodazole-arrested cells ([Fig. 1](#fig1){ref-type="fig"} C).

Many of the known APC/C substrates are also APC/C regulators ([@bib1]; [@bib5]; [@bib36]). This complicates the in vivo analysis of the proteolysis of these proteins because of the possibility that ectopic expression of these proteins during half-life measurements could itself alter APC/C function ([@bib1]).

Ase1p is a microtubule-binding and cross-linking protein that is required for the structural integrity of the anaphase spindle ([@bib16]; unpublished data). Although Ase1p is not expected to regulate APC/C, high levels of Ase1p activate the spindle assembly checkpoint and thereby might indirectly affect APC/C activity ([@bib16]; for review see [@bib2]). To create an inert reporter of APC^Cdh1^ activity, we constructed chimeras between Ase1p and glutathione *S*-transferase (GST). These chimeras enabled us to define the minimal Ase1p sequence necessary for APC^Cdh1^-mediated degradation. The half-lives of the GST--Ase1p fusions were measured in α-factor--arrested cells ([Fig. 2](#fig2){ref-type="fig"} A). A chimera containing the COOH-terminal 254 amino acids (R632-I885) of Ase1p was degraded with similar kinetics to full-length Ase1p. Further deletions up to amino acid 802 from the COOH-terminal end of R632-I885 were also rapidly degraded in α-factor--arrested cells. By contrast, deletion of 22 amino acids on the NH~2~-terminal side of the R632-I885 peptide resulted in a stable chimera (T654-I885; [Fig. 2](#fig2){ref-type="fig"} A). 7 of these 22 residues are lysines, raising the possibility that these may be the site(s) of Ase1p ubiquitination. Together, these results suggest that residues 632--802 comprise the minimal sequence for Ase1p degradation in α-factor--arrested cells.

###### 

**Ase1p domain sufficient for APC^Cdh1^-mediated degradation.** (A) Stability of Ase1p NH~2~-terminal truncations fused to GST in α-factor--arrested cells. Chimeras were expressed from the *GALL* promoter for 30 min in α-factor--arrested cells, and the half-lives of the chimeras were assayed. R632-I885 is the COOH-terminal 254 amino acids of Ase1p. (B) *CDC23* and *cdc23-1* strains containing *GAL1,10::C254* were arrested with α-factor, shifted to 36°C for 30 min to inactivate Cdc23p, then galactose was added for 30 min to induce expression of C254, and the half-life of the chimera was determined. (C) *cdc4* cells containing C254 or a db mutant of C254 (C254-db) were arrested at 36°C, and the half-lives of the fusion proteins were determined 30 min after the addition of galactose. (D) The half-life of C254 was determined in arrested *cdc4 cdh1*Δ*clb6*Δ and *cdc4 CDH1 clb6*Δ cells. (E) Cells constitutively expressing C254 (the GST--R632-I885 fusion protein) were prepared for immunofluorescence. No signal was detected in this strain grown under repressing conditions (glucose; data not shown). C254 is diffusely localized to the nucleus and appears to be at higher levels in mitotic cells.
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The degradation of the GST--R632-I885 fusion protein (hereafter referred to as C254) was characterized in more detail and found to have the characteristics of a bona fide APC^Cdh1^ substrate. Like wild-type Ase1p, C254 degradation in α-factor--arrested cells required Cdc23p and hence APC/C function ([Fig. 2](#fig2){ref-type="fig"} B). C254 degradation in α-factor--arrested cells also required the Ase1p destruction box and Cdh1p but was not affected by loss of Cdc20p (data not shown). Also, like wild-type Ase1p this fusion was stable in both S and G2/M phase--arrested cells (data not shown). Finally, as shown above for wild-type Ase1p, C254 was rapidly degraded in *cdc4*-arrested cells, and this degradation required the db and Cdh1p ([Fig. 2, C and D](#fig2){ref-type="fig"}). Thus, the degradation of C254 closely mimics that of Ase1p.

The localization of full-length Ase1p is restricted to the spindle midzone (the zone of overlap between the two half-spindles) ([@bib24]). By contrast, the C254 fusion protein localized diffusely throughout the nucleus and as expected did not complement an *ase1*Δ mutation ([Fig. 2](#fig2){ref-type="fig"} E; data not shown). Therefore, the specific localization of Ase1p on the mitotic spindle is not required for the normal timing of its degradation.

The finding that Ase1p was degraded by APC^Cdh1^ at the *cdc4* block suggested that G1 CDK activity was not sufficient to fully inactivate APC^Cdh1^. To monitor APC^Cdh1^ activity during a normal cell cycle, C254 was expressed from the *GALL* promoter ([@bib22]), a derivative of the *GAL1,10* promoter that is transcribed at low levels throughout the cell cycle when cells are grown in galactose-containing medium. Importantly, constitutive expression of C254 did not affect cell growth (data not shown) or cell cycle progression ([Fig. 3](#fig3){ref-type="fig"} A). Because transcription of C254 from this promoter was constant during the cell cycle ([Fig. 3](#fig3){ref-type="fig"} B), the steady-state level of C254 protein reflected its degradation.

###### 

**APC^Cdh1^ activity is inactivated during S phase.** (A) Constitutive expression of C254 does not alter the cell cycle. Strains constitutively expressing either GST or GST--R632-I885 (C254) from the *GALL* promoter by growth in galactose-containing medium were arrested with α-factor, collected by filtration, and released into the cell cycle. FACS^®^ analysis was performed at the indicated time points after release. (B) S phase stabilization of C254. A wild-type strain expressing C254 from the *GALL* promoter was grown in galactose-containing medium and arrested in α-factor and released into fresh medium. Samples were then collected for Western blotting, Northern blotting, and FACS^®^ analysis at the indicated time points. (C) *CLB5* and *clb5*Δ strains expressing C254 under the control of the *GALL* promoter were grown in galactose-containing medium, arrested in α-factor, released, and samples collected as in B.

![](0102007f3ab)

![](0102007f3c)

Analysis of C254 levels in synchronized cells suggested that APC^Cdh1^ is inactivated during S phase. Wild-type cells expressing C254 were released from a G1 block, and C254 levels were determined at intervals after release. Cell cycle position was monitored by Sic1p degradation, which occurs at the G1/S transition ([@bib34]), by the level of histone 2B mRNA, which is induced at S phase onset ([@bib12]), and by FACS^®^ analysis. We found that C254 accumulated after Sic1p was degraded, when histone 2B mRNA peaked and when FACS^®^ analysis demonstrated that cells had entered S phase ([Fig. 3](#fig3){ref-type="fig"} B).

Because APC^Cdh1^ appeared to be inactivated during S phase, we determined if removal of Clb5p, the major S phase cyclin ([@bib8]; [@bib33]), would affect the accumulation of C254. Consistent with a role for Clb5p in APC^Cdh1^ inactivation, C254 accumulation was delayed by ≥10 min in a *clb5*Δ strain ([Fig. 3](#fig3){ref-type="fig"} C). By contrast, deletion of *CLB3* and *CLB4*, which encode M phase cyclins, had no effect on the timing of C254 destruction (data not shown). Therefore, the normal timing of APC^Cdh1^ inactivation requires Clb5p.

We considered the possibility that ectopic expression of Clb2p could overcome the high levels of Sic1p in late G1-arrested cells and combine with G1 CDK activity to inactivate APC^Cdh1^. This could explain the difference between the timing of degradation of Ase1p and Clb2p. To test this idea, *cdc4* cells constitutively expressing low levels of Clb2p were synchronized with α-factor and released at 36°C to the *cdc4* arrest point in the presence or absence of hemagglutinin (HA)-tagged Sic1p overexpressed from the *GAL1,10* promoter ([@bib43]). As expected, Clb2p accumulated in the control culture ([Fig. 4](#fig4){ref-type="fig"} A, glu). However, Clb2p accumulation was prevented in the Sic1p-overexpressing culture ([Fig. 4](#fig4){ref-type="fig"}, compare αF with gal). Northern blot analysis showed that *CLB2* mRNA levels did not differ between the two cultures ([Fig. 4](#fig4){ref-type="fig"} A). We next measured the half-life of Clb2p in *cdc4*-arrested cells in the presence or absence of Sic1p overexpression. In the absence of Sic1p overexpression, Clb2p has a half-life of \>60 min, whereas with cooverexpression of Sic1p, Clb2p half-life is ∼20 min. FACS^®^ analysis showed that the cells remained arrested in G1 for ≥30 min after the samples were collected ([Fig. 4](#fig4){ref-type="fig"} B). Together, our results suggest that a combination of G1 cyclins and either S phase or M phase cyclins are required to inactivate APC^Cdh1^.

The persistence of APC^Cdh1^ activity through late G1 suggested that the degradation of certain APC^Cdh1^ substrates might be required for the normal execution of S phase. One appealing candidate for such a substrate is the APC activator Cdc20p. Metazoan Cdc20p is an APC^Cdh1^ substrate ([@bib27]; [@bib40]), and premature activation of APC^Cdc20^ might interfere with the expression of S phase cyclins. Indeed, we found that degradation of yeast Cdc20p is APC^Cdh1^ dependent in *cdc4*-arrested cells ([Fig. 5](#fig5){ref-type="fig"} A).

###### 

**APC^Cdh1^ regulation of Cdc20p expression.** (A) Cdc20p is an APC^Cdh1^ substrate in late G1. Expression of HA-tagged Cdc20p from the *GAL1,10* promoter ([@bib29]) was induced for 40 min, and the half-life of Cdc20p was determined in arrested *cdc4 cdh1*Δ*clb6*Δ and *cdc4 CDH1 clb6*Δ strains as for Ase1p in the legend to [Fig. 1](#fig1){ref-type="fig"} B. (B) Expression of stable Cdc20p in G1 delays S phase progression. Wild-type strains containing either vector alone or *GAL1,10::Cdc20*Δ*Box1*+*2-HA* ([@bib29]) were arrested with α-factor in YEP raffinose 3%. Expression from the *GAL1,10* promoter was induced for 30 min, and then cells were washed and released into YEP galactose 3%. (C) Inability to degrade Cdc20p in G1 delays S phase progression. Wild-type strains containing either *GAL1,10::Cdc20-HA* or *GAL1,10::Cdc20*Δ*Box1*+*2-HA* ([@bib29]) were arrested with α-factor in YEP raffinose 3%. Expression from the *GAL1,10* promoter was induced for 15 min, and then cells were washed and released into YEP galactose 2%. The levels of the HA-tagged Cdc20p and Cdc20ΔBox1+2 were determined by Western blotting and quantified as described in Materials and methods.
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To test the functional consequences of premature accumulation of Cdc20p during G1, we determined if inappropriate expression of Cdc20p in G1 affected cell cycle progression through S phase. Cells expressing Cdc20ΔBox1+2-HA from the p*GAL1,10* promoter were released into galactose-containing medium from a G1 block, and cell cycle transit was monitored by FACS^®^ analysis. By contrast with the control strain containing vector only, the Cdc20ΔBox1+2-expressing strain was delayed in transiting S phase ([Fig. 5](#fig5){ref-type="fig"} B). Next, we tested whether this delay in transiting S phase is due to the failure to degrade Cdc20p in G1 by comparing the cell cycle transit of strains expressing either wild-type Cdc20p or Cdc20ΔBox1+2. Compared with the Cdc20p-expressing strain, the Cdc20ΔBox1+2 strain was also delayed in transiting S phase ([Fig. 5](#fig5){ref-type="fig"} C). This delay correlates with the amount of Cdc20p that is expressed in G1 because Cdc20p was expressed at lower levels than Cdc20ΔBox1+2 until cells reached S phase ([Fig. 5](#fig5){ref-type="fig"} C). These experiments suggest that APC^Cdh1^ activity during G1 helps to ensure the proper timing of Cdc20p expression and thereby enables S phase progression to proceed with normal kinetics.

Discussion
==========

We found that APC^Cdh1^ is inactivated during S phase, and its complete inactivation requires Clb5p. Both Ase1p and Cdc20p were degraded in late G1-arrested cells containing high levels of G1 CDK activity. Cdh1p was required for the degradation of both substrates. We also found that a fraction of Cdh1p was bound to the APC/C in late G1-arrested cells. Further, the S phase cyclin Clb5p was required for the normal timing of APC^Cdh1^ inactivation. Thus, in a normal cell cycle the additive activities of G1 and S phase CDKs inactivate APC^Cdh1^. These findings have two implications for the design of the yeast cell cycle. First, the key role for Clb5p in APC^Cdh1^ inactivation suggests that Clb5p has an important role in enabling the expression of mitotic cyclins. This function was previously ascribed entirely to G1 cyclins. Second, because Clb5p is degraded by APC^Cdc20^ our finding that yeast Cdc20p is an APC^Cdh1^ substrate suggests that high APC^Cdh1^ activity throughout G1 may help ensure that Clb5p can accumulate sufficiently to drive a normal S phase.

Our conclusions differ from that of previous work using Clb2p degradation to monitor APC^Cdh1^ activity in vivo. The prior work suggested that G1 CDKs alone could inactivate what is now known to be APC^Cdh1^ ([@bib3]). The difference in the timing of Clb2p, Ase1p and Cdc20p degradation reported here could either be due to intrinsic differences in how these proteins are recognized by APC^Cdh1^ or to effects from the ectopic expression of Clb2p. Although we found that some Cdh1p is bound to APC/C in *cdc4*-arrested cells, considerably less is bound than in α-factor--arrested cells. It is therefore possible that APC^Cdh1^ is a more efficient enzyme for Ase1p and Cdc20p ubiquitination than for Clb2p ubiquitination. However, we also found that cooverexpression of Sic1p at the *cdc4* arrest point blocks Clb2p accumulation and restores Clb2p degradation in *cdc4*-arrested cells. This suggests that ectopic Clb/CDK activity was responsible for turning off the APC^Cdh1^ in the previous experiments. We therefore favor the idea that both G1- and B-type cyclin--associated kinases are required to fully inactivate APC^Cdh1^. Clb2p expressed in late G1 could either directly inactivate the APC^Cdh1^ or compete for Sic1p binding to S phase cyclins thereby freeing them to inhibit APC^Cdh1^.

How might G1 and S phase CDKs cooperate to inactivate APC^Cdh1^? Despite the presence of highly phosphorylated Cdh1p at the *cdc4* block, enough APC^Cdh1^ remains for rapid degradation of Ase1p and Cdc20p. Since Cdh1p has multiple functionally important CDK phosphorylation sites ([@bib48]; [@bib15]), G1 and S phase CDK might preferentially phosphorylate different sites or make an additive contribution to the total level of Cdh1p phosphorylation. Alternatively, the inhibitory effects of S phase CDK activity could be through phosphorylation of another substrate such as subunits of APC ([@bib30]). Whatever the mechanism for Clb5p-mediated inactivation of APC^Cdh1^, these results identify a novel Clb5p role in the inactivation of APC^Cdh1^ and by inference in the accumulation of mitotic cyclins.

These experiments also have implications for the relationship among Clb5p, APC^Cdh1^, and APC^Cdc20^. In both the *Xenopus* extract system and in cells overexpressing human Cdh1p, APC^Cdh1^ promotes the degradation of human Cdc20p ([@bib27]; [@bib40]). Our finding that yeast Cdc20p is also degraded by APC^Cdh1^ in late G1 demonstrates that this regulatory mechanism is conserved. Further, our in vivo experiments suggest that inappropriate expression of Cdc20p can delay progression through S phase. Therefore, we propose that the following regulation occurs at the G1/S transition. APC^Cdh1^ is active throughout G1. Clb5p accumulates in late G1, but Clb5/CDK activity is held in check by the presence of Sic1p ([@bib34]). After Sic1p is degraded, Clb5/CDK activity drives DNA replication and inactivates APC^Cdh1^. Because Cdc20p is an APC^Cdh1^ substrate, APC^Cdh1^ activity ensures that no Cdc20p is present to activate APC^Cdc20^ until after Clb5/CDK is active. It should be emphasized that degradation of Cdc20p by APC^Cdh1^ is one of several controls on Cdc20p expression as *CDC20* transcription is also low in G1 ([@bib29]; [@bib36]). Additionally, full APC^Cdc20^ activation also appears to require the phosphorylation of the APC/C itself ([@bib18]; [@bib39]; [@bib19]; [@bib30]). The existence of multiple overlapping control mechanisms is a common theme in the regulation of cell cycle transitions. We make the analogy to the regulation of mitotic exit where proteolysis, decreased transcription, and the expression of an inhibitor all collaborate to shut off mitotic cyclins.

Finally, our findings impact on the physiological role of Clb5p degradation by APC^Cdc20^. Mutant cells lacking Cdc20p but able to separate sister chromatids (*cdc20*Δ*pds1*Δ strains) cannot exit from mitosis ([@bib37]). However, these cells are able to exit mitosis if *CLB5* is deleted. Based on these findings, it was suggested that Cdc20p promotes mitotic exit in a normal cell cycle by degrading Clb5p, which in turn releases inhibition of Sic1p and Cdh1p. The results presented here raise the possibility that the role of Clb5p degradation in mitotic exit is indirect and occurs by suppression of mitotic cyclins. In the absence of Clb5p, APC^Cdh1^ may remain partially active, resulting in decreased levels of the mitotic cyclins Clb1p and Clb2p. In cells with reduced levels of mitotic cyclins, APC^Cdh1^ alone may be sufficient to trigger mitotic exit. The latter model is consistent with the established role of mitotic cyclin proteolysis in mitotic exit.

The APC/C is strikingly conserved among eukaryotes. The conservation of the APC/C is seen not only in the peptide sequence of its components and substrates but also extends to aspects of its regulation. Our results highlight what may be a general role for S phase cyclins in regulating APC^Cdh1^. In human cells, the S phase cyclin A complexed to Cdk1p phosphorylates and inactivates Cdh1p during S phase ([@bib21]). Thus, S phase inactivation of APC^Cdh1^ appears to be a conserved mechanism for control of the cell cycle.

Materials and methods
=====================

Strains and microbial techniques
--------------------------------

Media and genetic techniques were as described ([@bib35]). To arrest cells in late G1, *cdc4-1* cells were shifted to 36°C until \>90% of cells showed either multiple or elongated buds. To arrest cells in S or G2/M phase, hydroxyurea or nocodazole was added to a final concentration of 10 mg/ml or 15 μg/ml, respectively. To arrest cells in early G1, α-factor was added to a final concentration of 100 nM for *sst1* strains and 5 μM for *SST1* strains. To release cells from α-factor arrest, cells were collected by filtration, washed, and resuspended in fresh medium. All strains were derivatives of W303 except the A364α-derived *clb5* (a gift from F. Cross, The Rockefeller University, New York, NY) and *CLB5* control strains in [Fig. 3](#fig3){ref-type="fig"} C.

Mutagenesis and cloning
-----------------------

DNA manipulations were performed as described ([@bib31]). Ase1p truncations were generated by PCRs. The sequence of the oligonucleotide primers used for PCR are available upon request. All PCR-generated constructs were verified by DNA sequencing.

Half-life determination
-----------------------

Cells were arrested in medium containing 3% raffinose; galactose was added to a final concentration of 3% for 30--60 min, and then glucose (final concentration 3%) and cycloheximide (final concentration 1 mg/ml) were added to shut off transcription and translation. For proteins expressed from the *MET25* promoter, methionine (final concentration 1 mM) and cycloheximide were added. Protein samples were prepared from cells collected at the indicated time points and analyzed by Western blotting. Protein extracts were made as described ([@bib46]). Immunoblots were developed using ECL. Ase1p and derivatives were detected with either 9E10 ([@bib9]) for myc-tagged proteins or a rabbit polyclonal anti-Ase1p antibody ([@bib16]). myc-tagged Cdc16p was detected with 9E10. HA-tagged Clb2p, Cdh1p, and Cdc20p were detected with the 12CA5 monoclonal antibody ([@bib11]). Polyclonal antibodies were used to detect α-tubulin (Serotec), β-tubulin (a gift from F. Solomon, Massachusetts Institute of Technology, Cambridge, MA), and Sic1p (a gift from J.W. Harper, Baylor College of Medicine, Houston, TX). For quantification in [Fig. 4](#fig4){ref-type="fig"}, immunoblots were developed with ECL+, fluorescence was detected using StormImager (Molecular Dynamics), and signal intensities were measure using ImageQuant 5.0 software. For quantification in [Fig. 5](#fig5){ref-type="fig"}, immunoblots were probed with an IRDye800 fluorescent-labeled secondary antibody and quantitated on the Odyssey Infrared Imaging System (Li-Cor); fluorescence between blots was normalized to reference standards that were loaded on both blots.

Immunoprecipitation
-------------------

Strains containing myc-tagged Cdc16p (or untagged control) and HA-tagged Cdh1p were arrested at either 36°C (α-factor, *cdc4*) or 24°C (nocodazole). Cells were lysed using glass beads in IP buffer (50 mM Hepes, pH 7.3, 150 mM potassium acetate, 10 mM sodium fluoride, 1 mM EDTA, 1 mM PMSF, 20 mM β-glycerophosphate, 1 mM sodium vanadate, Phosphatase Inhibitor sets I and II \[Calbiochem\], 0.1% Triton X-100, and Complete™ protease inhibitors \[Roche\]). Extracts (2--4 mg) were incubated with 9E10 monoclonal antibodies (1,000:1) in IP buffer for 2 h at 4°C. Antibody-bound extracts were then incubated with protein G--plus agarose beads (Calbiochem) for 4 h at 4°C in IP buffer. The beads were washed five times with IP buffer and resuspended in sample buffer. Bound proteins were analyzed by SDS-PAGE and immunoblotting.

Flow cytometry
--------------

Cells were prepared for FACS^®^ analysis as described ([@bib24]) and analyzed on a FACScan™ using CellQuest software (Becton Dickinson).

Northern blotting
-----------------

RNA preparation, Northern blot analysis, and the probes to detect histone 2B1 and actin mRNA were as described ([@bib24]). The probe for *ASE1* mRNA was a 1.2-kb fragment from nucleotides 1896--3108 of the *ASE1* locus (where 1 is the A residue of the ATG codon).

Immunofluorescence
------------------

Cells were fixed and prepared for DAPI staining and immunofluorescence as described previously ([@bib28]). C254 containing three COOH-terminal myc tags was detected with 9E10.
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